You are here: Industry Insights > ImmunityBio

News List

ImmunityBio and Amyris conclude Covid-19 vaccine commercialisation JV Pharmaceutical-Technology
January 05, 2022
ImmunityBio and Amyris have concluded a joint venture (JV) agreement that was announced earlier to speed up the marketing of a next-generation vaccine for Covid-19.
Amyris, ImmunityBio Complete COVID-19 Vaccine Joint Venture contractpharma
January 03, 2022
Previously announced joint venture agreement accelerates commercialization of a next-generation COVID-19 vaccine.
ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2 americanpharmaceuticalreview
April 12, 2021
ImmunityBio, Inc., a clinical-stage immunotherapy company, reported initial data indicating that a single subcutaneous injection of the company’s COVID-19 vaccine candidate in healthy Phase 1 clinical study participants stimulates the generation of ...
ImmunityBio Simulations give clue to why South African strain of SARS-CoV-2 is rapidly spreading expresspharma
January 20, 2021
Using Molecular Dynamic (MD) simulation, ImmunityBio scientists assessed the affinity of mutated spike receptor binding domain (RBD) of SARS-CoV-2 to its receptor on human cells, ACE2.
iosBio Inks Exclusive Vax Platform Pact for COVID-19 contractpharma
January 13, 2021
OraPro oral delivery vaccine platform technology enables oral administration of thermally-stable, viral vector vaccines.
ImmunityBio and NantKwest announce merger expresspharma
December 22, 2020
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms.
ImmunityBio COVID-19 vaccine candidate shows protection of airways in non-human primates expresspharma
December 14, 2020
The hAd5-COVID-19 candidate is designed to address a potential problem that may emerge when first-generation adenoviral platforms are used as vaccine vectors: vaccine inactivation due to pre-existing immunity to the vector itself.
ImmunityBio reports positive data from Covid-19 vaccine trial pharmaceutical-technology
November 11, 2020
ImmunityBio has reported positive study results for its novel vaccine candidate, hAd5-COVID-19, which showed memory T-cell recall from patients previously infected with SARS-CoV-2, a virus that causes Covid-19.
ImmunityBio, NantKwest begin patient dosing in Phase 1 clinical trial of COVID-19 vaccine candidate expresspharma
October 22, 2020
The Phase 1 trial, being conducted at the Hoag Hospital in Newport Beach, California, is enrolling healthy adult subjects up to age 55 to examine the safety and reactogenicity of two doses of the vaccine candidate.
ImmunityBio’s hAd5 vaccine candidate for Covid-19 succeeds in preclinical study pharmaceutical-business-review
August 06, 2020
ImmunityBio said that its human Ad5 vaccine candidate (hAd5 vaccine candidate), which is being developed for the prevention of Covid-19, has yielded positive preclinical results.

Previous page 1 2 Next page